PharmExec

JANUARY 9, 2023

The Anglo-Swedish drugmaker on Monday agreed to pay $26 per CinCor share in cash, or $1.3 billion in total, a premium of nearly 121% to the U.S.-based based company's closing price on Friday.

52

52

Fierce Pharma

JULY 28, 2023

Is AstraZeneca planning to peel off its China business? Is AstraZeneca planning to peel off its China business? By CEO Pascal Soriot’s response to that question, it may only a contingency plan. | By CEO Pascal Soriot’s response to that question, it may only be a contingency plan.

85

85

Fierce Pharma

JUNE 22, 2023

AstraZeneca has reportedly drafted a contingency plan to spin out its China business amid increasing geopolitical risks. AstraZeneca has reportedly worked out a contingency plan to spin out its China business amid increasing geopolitical risks.

83

83

STAT

APRIL 1, 2024

… AstraZeneca’s plan to pay chief executive officer Pascal Soriot up to £18.7 Since taking the helm in 2012, Soriot has turned AstraZeneca into the second-largest company on the FTSE 100 index and last year received £16.9 We hope your day is meaningful and productive. And as always, do keep in touch.

81

81

Fierce Pharma

JUNE 20, 2023

AstraZeneca, the largest multinational pharma company in China, has reportedly made plans to separate its local business there in case geopolitical tensions worsen. | The largest multinational pharma company in China has reportedly made plans to separate its local business in case geopolitical tensions worsen.

96

96

STAT

APRIL 25, 2024

The need-to-know this morning AstraZeneca reported first-quarter  sales and profits  that topped analyst estimates, buoyed by its blockbuster cancer drugs. It’s a busy day for pharma earnings:  Merck ,  Sanofi ,  Daiichi Sankyo ,  Astellas , and  Bristol Myers Squibb.

Hospitals 98

Hospitals 98

PharmExec

JUNE 13, 2022

Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).

98

98

The Guardian - Pharmaceutical Industry

DECEMBER 12, 2023

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business AstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid-19 pandemic.

Vaccines 46

Vaccines Immunization 46

The Guardian - Pharmaceutical Industry

MARCH 19, 2024

Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments Business live – latest updates Britain’s biggest drugmaker, AstraZeneca, is to buy a Canadian cancer specialist focused on next-generation treatments for $2.4bn (£1.9bn), the latest in a string of acquisitions made to strengthen its portfolio of new (..)

Chemotherapy 49

Chemotherapy 49

STAT

FEBRUARY 8, 2024

On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.  

96

96

Fierce Pharma

OCTOBER 26, 2023

In a busy week for the antibody-drug conjugate (ADC) field, Merck signed a three-drug deal with Daiichi Sankyo but abandoned two preclinical assets from Kelun-Biotech. | In a busy week for the antibody-drug conjugate (ADC) field, Merck signed a three-drug deal with Daiichi Sankyo but abandoned two preclinical assets from Kelun-Biotech.

52

52

Pharma Marketing Network

JULY 17, 2023

Jerry Valentine has over 15 years of pharmaceutical experience, including establishing relationships across marketing teams, agency partners, and extending business teams to implement multi-channel marketing programs for HCPs and consumers.

52

52

Pharmaceutical Technology

AUGUST 8, 2022

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

FDA 105

FDA Chemotherapy Labelling 105

Fierce Pharma

AUGUST 3, 2023

AstraZeneca CEO responded to a report about the company's plan to spin out its China business. . | Bristol Myers Squibb and BeiGene decided to terminate their three-drug licensing deal. Sumitomo Pharma's Otsuka-partnered schizophrenia candidate ulotaront failed in two phase 3 trials. And more.

52

52

Pharmaceutical Technology

SEPTEMBER 9, 2022

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). The post Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure appeared first on Pharmaceutical Technology.

Compounding 98

Compounding 98

European Pharmaceutical Review

FEBRUARY 22, 2023

European Pharmaceutical Review recently spoke to Miriam Guest, Principal Microbiologist at AstraZeneca UK, who has been involved in work to establish a short-, mid- and long-term strategy to optimise BET across the global business.

90

90

STAT

MARCH 19, 2024

Rise and shine, everyone, another busy day is on the way. … AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the blooming area of targeted radiation therapies for cancer , STAT writes. Just keep scrolling down. And as always, do keep in touch.

95

95

Pharmaceutical Technology

JANUARY 27, 2023

The European Union (EU) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (trastuzumab deruxtecan) as monotherapy to treat unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer adult patients. It has been developed using the DXd ADC technology from Daiichi Sankyo.

Chemotherapy 94

Chemotherapy 94

Pharmaceutical Technology

AUGUST 12, 2022

The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults.

FDA 105

FDA Chemotherapy 105

European Pharmaceutical Review

FEBRUARY 22, 2023

AstraZeneca’s tablet formulation of Calquence (acalabrutinib) has been approved in the European Union (EU) for adults with chronic lymphocytic leukaemia (CLL). According to AstraZeneca, in B cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion.

77

77

Pharmaceutical Technology

DECEMBER 19, 2022

Business Expansion. Business Expansion is one of our largest categories and looks at the core functions of business operations within the sector. AstraZeneca/Daiichi Sankyo Nokia Bell Labs andEquideum Health Oak Hill Bio. AbbVie AstraZeneca Eli Lilly/Boehringer Fennec Moderna Novartis Pfizer Sanofi Teoxane.

52

52

European Pharmaceutical Review

MARCH 7, 2024

AstraZeneca to boost cell therapy operations with $300m manufacturing investment Advancing the UK’s life sciences sector The Chancellor also confirmed that companies will soon be able to apply for a share of the £520 million funding for life sciences manufacturing announced at Autumn Statement.

Pharmaceutical Companies 94

Pharmaceutical Companies Pharmaceutical Companies Packaging Vaccines 94

European Pharmaceutical Review

MAY 1, 2024

The Digital Membership includes companies such as GSK, AstraZeneca, The National Physical Laboratory, The University of Cambridge, Quotient Sciences, The University of Strathclyde and Thermo Fisher.

Vaccines 84

Vaccines 84

pharmaphorum

SEPTEMBER 1, 2022

AstraZeneca has succeeded in a last-gasp effort to stop its former head of investor relations joining rival UK pharma group GSK, after winning an injunction in the High Court in London. ” It’s not the first time that AZ has taken legal action to try to prevent one of its former executives making the move to its rival.

104

104

pharmaphorum

JULY 14, 2022

Bayer’s venerable testosterone replacement product for men with hypogonadism – Nebido – is being sold to Grünenthal as the group continues a revamp of its healthcare business. It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name.

97

97

pharmaphorum

MAY 7, 2021

She will oversee the strategy for several clients, and she’ll manage a team that works across all business units in order to ensure The Bloc’s competitive differentiation is present for each client. Antoinette earned a BS from Georgetown University and an MBA from the Fordham University Graduate School of Business in New York City.

Vaccines 98

Vaccines 98

pharmaphorum

SEPTEMBER 18, 2020

AstraZeneca is a company with a turbulent history but, for now, a promising future. In 1998, Europe’s corporate landscape was riding a “merger wave” – intensive competitive pressure meant that opportunities arose for companies to merge with their competitors in order to rationalise both businesses. Zeneca Group plc.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 116

Pharmaceutical Technology

DECEMBER 29, 2022

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved AstraZeneca ’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) to treat advanced liver, biliary tract, and lung cancers. The combination of Imfinzi and Imjudo has been approved to treat unresectable hepatocellular carcinoma (HCC) in adult patients.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

DECEMBER 1, 2020

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. AstraZeneca will also continue selling the medicine in other countries, including those in North America, Japan, China and other emerging markets.

82

82

pharmaphorum

MAY 31, 2022

The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection with its 2019 deal to acquire rights to Daiichi Sankyo’s breast cancer therapy Enhertu. The post SEC accuses former AstraZeneca exec of insider trading appeared first on. Sanofi/Kadmon case.

Communication 97

Communication 97

European Pharmaceutical Review

DECEMBER 12, 2023

Yannis Morel, Executive Vice President of product portfolio strategy and business development of Innate Pharma SA, offers insight on engineering antibodies to develop antibody-based NK cell therapeutics. Innate Pharma also developing IPH5201 in collaboration with AstraZeneca. He is a member of the company’s Executive Board.

Immunization 100

Immunization Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 100

European Pharmaceutical Review

MARCH 27, 2024

With one success factor of Swedish life sciences being the export numbers, “in majority driven by AstraZeneca”, Maja Neiman, Scientific Director of SwedenBIO explained to EPR that another important influence is “the high numbers and potential of [Sweden’s] domestic innovation pipeline”. What could the future hold?

78

78

Pharmaceutical Technology

DECEMBER 22, 2022

Our programme is designed to highlight excellence within the sector by looking at a range of corporate activities including deals, business projects and company initiatives, both internal and in the community. Business Expansion. AstraZeneca/Daiichi Sankyo Nokia Bell Labs andEquideum Health Oak Hill Bio. Environmental.

FDA 52

FDA Insurance Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 1, 2023

The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD ’s Lynparza (olaparib), with standard therapies for treating BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). A prior orchiectomy or receipt of gonadotropin-releasing hormone (GnRH) analogs was also necessary.

FDA 97

FDA Chemotherapy 97

European Pharmaceutical Review

JANUARY 26, 2023

It is being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. The approval is indicated for those who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Chemotherapy 73

Chemotherapy 73

pharmaphorum

OCTOBER 20, 2020

It’s not clear which vaccine will be involved in the study – there are several in the last stages of clinical development and the UK government has orders for candidates from AstraZeneca, Pfizer/BioNTech, Novavax, Valneva, Sanofi/GSK and Johnson & Johnson. No financial details of the contract with hVIVO were disclosed.

Vaccines 98

Vaccines 98

pharmaphorum

MARCH 1, 2021

AstraZeneca has sold its stake in Moderna for more than $1 billion as the US biotech’s shares soared in value following its coronavirus vaccine breakthrough. billion windfall will be a boost to the UK pharma’s coffers during a busy time. The UK-based pharma has disposed of its 7.7% billion in US government funding.

Vaccines 64

Vaccines 64